EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The late-onset Alzheimer’s disease risk factor RHBDF2 is a modifier of microglial TREM2 proteolysis

Georg Jocher iD, Gozde Ozcelik, Stephan A Müller, Hung-En Hsia, Miranda Lastra Osua, Laura I Hofmann, Marlene Aßfalg, Lina Dinkel, Xiao Feng, Kai Schlepckow, Michael Willem, Christian Haass und 3 weitere

Life Science Alliance · 2025

DOI: 10.26508/lsa.202403080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Science Alliance, 2025. Verfasst von Georg Jocher und 14 weiteren Autor:innen. Beteiligte Einrichtung: https://ror.org/043j0f473 German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. Hauptthemen laut MEDLINE: Microglia, Receptors, Immunologic, Alzheimer Disease, Membrane Glycoproteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Deutsche Forschungsgemeinschaft, Alzheimer Forschung Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cell surface receptor TREM2 is a key genetic risk factor and drug target in Alzheimer’s disease (AD). In the brain, TREM2 is expressed in microglia, where it undergoes proteolytic cleavage, linked to AD risk, but the responsible protease in microglia is still unknown. Another microglial-expressed AD risk factor is catalytically inactive rhomboid 2 (iRhom2, RHBDF2), which binds to and acts as a non-catalytic subunit of the metalloprotease ADAM17. A potential role in TREM2 proteolysis is not yet known. Using microglial-like BV2 cells, bone marrow–derived macrophages, and primary murine microglia, we identify iRhom2 as a modifier of ADAM17-mediated TREM2 shedding. Loss of iRhom2 increased TREM2 in cell lysates and at the cell surface and enhanced TREM2 signaling and microglial phagocytosis of the amyloid β-peptide (Aβ). This study establishes ADAM17 as a physiological TREM2 protease in microglia and suggests iRhom2 as a potential drug target for modulating TREM2 proteolysis in AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicrogliaReceptors, ImmunologicAlzheimer DiseaseMembrane GlycoproteinsCarrier ProteinsAnimalsProteolysisMiceADAM17 ProteinHumansAmyloid beta-PeptidesPhagocytosisMacrophagesRisk FactorsSignal TransductionMice, Inbred C57BL

Substanzen

Receptors, ImmunologicMembrane GlycoproteinsADAM17 ProteinTrem2 protein, mouseAmyloid beta-PeptidesiRhom2 protein, mouseTREM2 protein, humanCarrier Proteins

Autor:innen und Institutionen

  • https://ror.org/043j0f473 German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • https://ror.org/02kkvpp62 Neuroproteomics, School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
  • Department of Medicine and Department of Biochemistry, Cellular and Molecular Biology, Weill Cornell Medicine, New York, NY, USA.
  • Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, USA.

ORCID-Profile: Georg Jocher, Carl P Blobel, Stefan F Lichtenthaler

Förderung

  • NIGMS NIH HHS
  • Deutsche Forschungsgemeinschaft
  • Alzheimer Forschung Initiative
  • Centers of Excellence in Neurodegeneration
  • Friedrich Naumann Stiftung
  • HHS | National Institutes of Health

Zitieren

APA

Jocher, G., Ozcelik, G., Müller, S. A., Hsia, H. E., Lastra Osua, M., Hofmann, L. I., Aßfalg, M., Dinkel, L., Feng, X., Schlepckow, K., Willem, M., Haass, C., Tahirovic, S., Blobel, C. P., & Lichtenthaler, S. F. (2025). The late-onset Alzheimer’s disease risk factor RHBDF2 is a modifier of microglial TREM2 proteolysis. Life Science Alliance. https://doi.org/10.26508/lsa.202403080

Vancouver

Jocher G, Ozcelik G, Müller SA, Hsia HE, Lastra Osua M, Hofmann LI, et al. The late-onset Alzheimer’s disease risk factor RHBDF2 is a modifier of microglial TREM2 proteolysis. Life Science Alliance. 2025. doi:10.26508/lsa.202403080

BibTeX
@article{Jocher2025,
  author = {Jocher, Georg and Ozcelik, Gozde and Müller, Stephan A and Hsia, Hung-En and Lastra Osua, Miranda and Hofmann, Laura I and Aßfalg, Marlene and Dinkel, Lina and Feng, Xiao and Schlepckow, Kai and Willem, Michael and Haass, Christian and Tahirovic, Sabina and Blobel, Carl P and Lichtenthaler, Stefan F},
  title = {The late-onset Alzheimer’s disease risk factor RHBDF2 is a modifier of microglial TREM2 proteolysis},
  journal = {Life Science Alliance},
  year = {2025},
  doi = {10.26508/lsa.202403080}
}
Kostenlos starten →